

EPAの補給によりADHD児の教師評価行動および反抗症状が改善される 9/9

ADHDにおけるEPAに関するRCT

謝辞

すべての参加小児・親、医師、看護師、教師、試験統計の専門家Martin Ålenius、スポンサーのHela Pharma AB、Minami Nutrition、Qb-tech medical engineering company、Medical Research Council of Southeast Sweden(FORSS-5539)に感謝いたします。Berit Holmbergによる優れた技術に深く感謝いたします。

References

1. American Psychiatric Association AP. Diagnostic and statistical manual of mental disorders. 4 ed. Washington, DC: American Psychiatric Association; 1994.
2. Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. *J Am Acad Child Adolesc Psychiatry* 2000;39:1424-31.
3. Doggett AM. ADHD and drug therapy: is it still a valid treatment? *J Child Health Care* 2004;8:69-81.
4. Antal CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. *Prostaglandins Leukot Essent Fatty Acids* 2006;75:299-308.
5. Burgess JR, Stevens L, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. *Am J Clin Nutr* 2000;71:3 27S-30S.
6. Spahis S, Vanasse M, Belanger SA, Ghadirian P, Grenier E, Levy E. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. *Prostaglandins Leukot Essent Fatty Acids* 2008;79:47-53.
7. Bourre JM. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. *J Nutr Health Aging* 2004;8:163-74.
8. Haag M. Essential fatty acids and the brain. *Can J Psychiatry* 2003;48:195-203.
9. Crawford MA. The role of essential fatty acids in neural development: implications for perinatal nutrition. *Am J Clin Nutr* 1993;57:703S-9S.
10. Chalon S, Vancassel S, Zimmer L, Guilleateau D, Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. *Lipids* 2001;36:937-44.
11. Hulbert AJ. Life, death and membrane bilayers. *J Exp Biol* 2003;206:2303-11.
12. Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. *J Neurosci Res* 1999;56:565-70.
13. Joardar A, Sen AK, Das S. Docosahexaenoic acid facilitates cell maturation and beta-adrenergic transmission in astrocytes. *J Lipid Res* 2006;47:571-81.
14. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. *Int Rev Psychiatry* 2006;18:155-72.
15. Stordy BJ. Dark adaptation, motor skills, docosahexaenoic acid, and dyslexia. *Am J Clin Nutr* 2000;71:323S-6S.
16. Richardson AJ, Montgomery P. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. *Pediatrics* 2005;115:1360-6.
17. Amminger GP, Berger GE, Schaefer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. *Biol Psychiatry* 2007;61:551-3.
18. Curtis LT, Patel K. Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): a review. *J Altern Complement Med* 2008;14:79-85.
19. Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by Efamol in hyperactive children. *J Abnorm Child Psychol* 1987;15:75-90.
20. Arnold LE, Kleykamp D, Votolato NA, Taylor WA, Kontras SB, Tobin K. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. *Biol Psychiatry* 1989;25:222-8.
21. Colter AL, Cutler C, Meckling KA. Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents: a case-control study. *Nutr J* 2008;7:8.
22. Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. *Eur J Clin Nutr* 2004;58:467-73.
23. Johnson M, Ostlund S, Fransson G, Kadesjo B, Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. *J Atten Disord* 2009;12:394-401.
24. Richardson AJ, Puri BK. A randomized double-blind, placebo-

controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26:233-9.

25. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. *J Dev Behav Pediatr* 2007;28:82-91.

26. Sinn N, Bryan J, Wilson C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. *Prostaglandins Leukot Essent Fatty Acids* 2008;78:311-26.

27. Sorgi PJ, Hollowell EM, Hutchins HL, Sears B. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. *Nutr J* 2007;6:16.

28. Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, et al. EPA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. *Lipids* 2003;38:1007-21.

29. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. *J Pediatr* 2001;139:189-96.

30. Conners CK. Conners' Rating scales manual. System M-H, editor. Toronto1990.

31. Seidman LJ. Neuropsychological functioning in people with ADHD across the lifespan. *Clin Psychol Rev* 2006;26:466-85.

32. Landgren M, Kjellman B, Gillberg C. Deficits in attention, motor control and perception (DAMP): a simplified school entry examination. *Acta Paediatr* 2000;89:302-9.

33. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD rating scale-IV: Checklists, norms, and clinical interpretations. New York: Guilford; 1998.

34. Raven JC. Coloured Progressive Matrices Press OP, editor. Oxford, 1995.

35. Teicher MH, Ito Y, Glod CA, Barber NI. Objective measurement of hyperactivity and attentional problems in ADHD. *J Am Acad Child Adolesc Psychiatry* 1996;35:334-42.

36. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* 1957;226:497-509.

37. Gronowitz E, Mellstrom D & Strandvik B (2006) Serum phospholipid fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis. *Br J Nutr* 95, 1159-1165.

38. Gow RV, Matsudaira T, Taylor E, Rubia K, Crawford M, Ghebremeskel K, et al. Total red blood cell concentrations of omega-3 fatty acids are associated with emotion-elicited neural activity in adolescent boys with attention-deficit hyperactivity disorder. *Prostaglandins Leukot Essent Fatty Acids* 2009;80:151-6.

39. Gustafsson PA, Duchon K, Birberg U, Karlsson T. Breastfeeding, very long polyunsaturated fatty acids (PUFA) and IQ at 6 1/2 years of age. *Acta Paediatr* 2004;93:1280-7.

40. Brookes KJ, Chen W, Xu X, Taylor E, Asherson P. Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder. *Biol Psychiatry* 2006;60:1053-61.

41. Schaeffer L, Gohlke H, Muller M, Heid IM, Palmer LJ, Kompauer I, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. *Hum Mol Genet* 2006;15:1745-56.

42. Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. *Am J Clin Nutr* 1997;66:649-59.

43. Brown ER, Subbiah PV. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on human skin fibroblasts. *Lipids* 1994;29:825-9.

44. Hamazaki T, Hirayama S. The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder-a placebo-controlled double-blind study. *Eur J Clin Nutr* 2004;58:838.

45. Obajimi O, Black KD, MacDonald DJ, Boyle RM, Glen I, Ross BM. Differential effects of eicosapentaenoic and docosahexaenoic acids upon oxidant-stimulated release and uptake of arachidonic acid in human lymphoma U937 cells. *Pharmacol Res* 2005;52:183-91.

46. Hibbeln JR, Ferguson TA, Blasbalg TL. Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation: opportunities for intervention. *Int Rev Psychiatry* 2006;18:107-18.

47. Simopoulos AP. Evolutionary aspects of omega-3 fatty acids in the food supply. *Prostaglandins Leukot Essent Fatty Acids* 1999;60:421-9.

48. Innis SM. Polyunsaturated fatty acids in human milk: an essential role in infant development. *Adv Exp Med Biol* 2004 ;554:27-43.

Product on the Paper

MorDHA® PRENATAL

モアDHA® プレネイタル

品 番：EP.050.xxx
価 格：5,900円(税別)
内 容 量：60粒入 1日1粒/60日分

妊娠を望む方、妊娠中、授乳中の方に安全なDHA

妊娠中は母体の持っているDHAの半分が胎児の発育のために使われてしまい、DHAの必要量が増加します。また、妊娠中は胎児に有害な重金属等の毒素を含有する可能性がある魚の摂取を避けるべきで、そのため、DHAを食事の中から摂取することが難しくなります。【モアDHA®】は、母子の健康や胎児の発育に大変重要な働きをするDHAを安全に摂取することが可能です。

主成分含有量 (1ソフトカプセルあたり)

成分名	含有量
オメガ3脂肪酸(以下の成分を含む)	640 mg
ドコサヘキサエン酸(DHA)	480 mg
エイコサペンタエン酸(EPA)	104 mg



MorEPA® SMART FATS FISH OIL

モアEPA® スマート ファッツ フィッシュ オイル

品 番：EP.011.xxx
価 格：4,000円(税別)
内 容 量：30粒入り/1日1粒/30日分

肉体的、精神的な健康維持、健康な関節や美肌をサポート

【モアEPA®】は高濃度EPAの最も基本となるオメガ3フィッシュオイルです。血管の健康維持に大切なオメガ3脂肪酸は健康な心臓、良好な気分や情緒の安定をサポート、物事に向かう強い集中力を生み出します。精神集中に使用するフィッシュオイルに関する多くの臨床検査結果から、【モアEPA®】が脂肪酸バランスの回復に有用で、情緒の安定と集中力をサポートするという事実は科学的に証明されています。

主成分含有量 (1ソフトカプセルあたり)

成分名	含有量
オメガ3脂肪酸(以下の成分を含む)	850 mg
エイコサペンタエン酸(EPA)	590 mg
ドコサヘキサエン酸(DHA)	130 mg

※臨床データがございますので、ご入用の際は申し付けください。



Order Made Supplement Service

分包による
オーダーメイド
サプリメント
サービス！

- 患者様に合わせた指示箋ができる、オーダーメイド分包サービスです。患者様の満足度がより高くなります。
- 在庫負担がありません。
- 商品のお届けは、クリニック様お届けと患者様直送からお選び頂けます。
- ラベルデザインや容器も色々お選び頂けます。



編集後記

ダグラスニュースレターをお読みいただき誠にありがとうございました。これからも最新の臨床データ、商品情報などを正確に、また、迅速にご提供してまいります。どちら様もご意見・ご希望がございましたら編集者までお寄せください。

無断転載・転用は固くお断りいたします。

発行者：
〒135-0091 東京都港区台場2-3-2
日本ダグラスラボラトリーズ株式会社
TEL: 03-5530-2212